Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized p...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer Vol. 19; no. 1; pp. 816 - 15
Main Authors: Palma, David A., Olson, Robert, Harrow, Stephen, Correa, Rohann J. M., Schneiders, Famke, Haasbeek, Cornelis J. A., Rodrigues, George B., Lock, Michael, Yaremko, Brian P., Bauman, Glenn S., Ahmad, Belal, Schellenberg, Devin, Liu, Mitchell, Gaede, Stewart, Laba, Joanna, Mulroy, Liam, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Warner, Andrew, Slotman, Ben J., de Gruijl, Tanja D., Allan, Alison, Senan, Suresh
Format: Journal Article
Language:English
Published: London BioMed Central 19.08.2019
BioMed Central Ltd
BMC
Subjects:
ISSN:1471-2407, 1471-2407
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first